Testing a new antifungal strategy for talaromycosis
Treatments studied
Part of Infections clinical trials.
This study tests whether a combination of two antifungal drugs works well for treating talaromycosis, a serious fungal infection common in people with HIV. The goal is to find a more convenient and effective treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have HIV
- You have a confirmed talaromycosis infection (diagnosed by a lab test)
- You are not allergic to the study drugs (amphotericin B or flucytosine)
- You do not have severe low white blood cell counts (neutrophils below 500)
- You do not have cryptococcal or TB meningitis at the same time
- You have not already received more than 2 doses of deoxycholate amphotericin B for this infection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a single high dose of a potent antifungal medicine (liposomal amphotericin B) combined with a modern HIV treatment (B/F/TAF) for people with HIV who have a serious fungal infection called talaromycosis. The goal is to see if this short, powerful treatment works well and is safe.
This study tests whether a one-time antifungal treatment can help people with HIV who have a positive cryptococcal antigen blood test but no symptoms. It may lower the chance that this infection becomes a serious illness affecting the brain.
This trial tests the drug amphotericin B for people with cryptococcal meningitis who do not have HIV. The goal is to see if this treatment is safe and effective.
This trial is testing new treatments for cryptococcal meningitis, a serious brain infection, in people living with HIV. It aims to find the best way to treat this infection with fewer side effects.
This Phase 3 trial tests whether a high-dose form of amphotericin B made in tiny fat particles (liposomal amphotericin B) is safer and more effective for treating widespread Histoplasmosis in adults with HIV. It may help people who have a serious, whole-body infection caused by Histoplasma.
This trial looks at how a specific antifungal medicine, called liposomal amphotericin B, given over a longer period, helps prevent serious fungal infections in people undergoing treatment for cancer or receiving a stem cell transplant. It may be an option if you are at high risk for these infections.
Hear when a new Talaromycosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.